ReleaseWire

Global Markets Direct's, 'Syntiron LLC - Product Pipeline Review - 2014', provides an overview of the Syntiron LLC's pharmaceutical research and development focus.

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H2 2014', provides an overview of the Raynauds Disease's therapeutic pipeline.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Global Markets Direct's, 'X-BODY BioSciences, Inc. - Product Pipeline Review - 2014', provides an overview of the X-BODY BioSciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Virometix AG - Product Pipeline Review - 2014', provides an overview of the Virometix AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

Global Markets Direct's, 'Sensorion S.A.S. - Product Pipeline Review - 2014', provides an overview of the Sensorion S.A.S.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AtheroNova Inc. - Product Pipeline Review - 2014', provides an overview of the AtheroNova Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Promius Pharma, LLC - Product Pipeline Review - 2014', provides an overview of the Promius Pharma, LLC's pharmaceutical research and development focus.

Global Markets Direct's, 'Lipotek Pty Ltd. - Product Pipeline Review - 2014', provides an overview of the Lipotek Pty Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Nonmelanomatous Skin Cancer - Pipeline Review, H2 2014', provides an overview of the Nonmelanomatous Skin Cancer's therapeutic pipeline.

Global Markets Direct's, 'Toyama Chemical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Toyama Chemical Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'NKT Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NKT Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014', provides an overview of the Pancreatic Ductal Adenocarcinoma's therapeutic pipeline.

Global Markets Direct's, 'SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the SymBio Pharmaceuticals Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Heron Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Heron Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'GliaCure Inc. - Product Pipeline Review - 2014', provides an overview of the GliaCure Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'ImmuRx, Inc. - Product Pipeline Review - 2014', provides an overview of the ImmuRx, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Neurotez, Inc. - Product Pipeline Review - 2014', provides an overview of the Neurotez, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alitair Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Kite Pharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Kite Pharma, Inc.'s pharmaceutical research and development focus.

Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.

Global Markets Direct's, 'NovaRx Corporation - Product Pipeline Review - 2014', provides an overview of the NovaRx Corporation's pharmaceutical research and development focus.

Global Markets Direct's, 'ImmuVen, Inc. - Product Pipeline Review - 2014', provides an overview of the ImmuVen, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Kolltan Pharmaceuticals, Inc.'s pharmaceutical research and development focus.